Drug intelligence / Profile preview

Enomeral

Development stage: Unknown
Lead developer: Taha Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Enomeral** is an oral gastro-resistant capsule product marketed by **Taha Pharma** in Tunisia that contains **esomeprazole**, a **small-molecule proton pump inhibitor**. It suppresses gastric acid secretion by inhibiting the gastric **H+/K+-ATPase proton pump** in parietal cells, and is used for acid-related disorders including **gastroesophageal reflux disease**, **erosive esophagitis**, **duodenal ulcer**, **gastric ulcer**, and **Zollinger-Ellison syndrome**. It is also used in **Helicobacter pylori** eradication regimens with antibiotics and for prevention of **NSAID-associated gastric ulceration**. The product is available in **20 mg** and **40 mg** gastro-resistant capsule strengths.

Brand names: Enomeral

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Enomeral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enomeral.

Explore the full profile